Zobrazeno 1 - 10
of 397
pro vyhledávání: '"I E Smith"'
Autor:
S. Stenler, K. E. Lundin, L. Hansen, S. Petkov, N. Mozafari, M. Isaguliants, P. Blomberg, C. I. E. Smith, D. M. Goldenberg, C.-H. Chang, K. Ljungberg, J. Hinkula, B. Wahren
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 13, Iss 12, Pp 2849-2858 (2017)
Background: Genetic immunization is expected to induce the expression of antigens in a native form. The encoded peptide epitopes are presented on endogenous MHC molecules, mimicking antigen presentation during a viral infection. We have explored the
Externí odkaz:
https://doaj.org/article/ba7e0ede7ccb4c2db071810eddf1238f
Publikováno v:
Cancer Research. 78:P3-13
This abstract was withdrawn by the authors.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8514633b5a85174916b5b89d025a8581
https://doi.org/10.1158/1538-7445.sabcs17-p3-13-01
https://doi.org/10.1158/1538-7445.sabcs17-p3-13-01
Autor:
I. E. Smith, Lila Zabaglo, Mitchell Dowsett, Elena Lopez-Knowles, Judith M Bliss, Elizabeth Mallon, Qiong Gao, M Tomiczek, James P Morden, Mcu Cheang, Joel Parker, J.F.R. Robertson, Margaret Hills, Simone Detre
Publikováno v:
Cancer Research. 77:P2-10
Background Neoadjuvant endocrine therapy (NAE) is often a good option for postmenopausal (PM) women with estrogen receptor positive (ER+) breast cancers(BC). Fall in Ki67 is widely accepted as valid for predicting favorable tumor response to NAE and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5f0a31b9d93ebd7321515f47eee1308d
https://doi.org/10.1158/1538-7445.sabcs16-p2-10-02
https://doi.org/10.1158/1538-7445.sabcs16-p2-10-02
Autor:
Anthony Skene, Judith M Bliss, Mcu Cheang, Qiong Gao, D G R Evans, James P Morden, L-A Martin, J.F.R. Robertson, Elena Lopez-Knowles, V Martins, I. E. Smith, Christopher Holcombe, Elizabeth Mallon, Kally Sidhu, Mitchell Dowsett, Andrew Dodson, E Abigail
Publikováno v:
Cancer Research. 77:P2-09
BACKGROUND Gene expression (expr) analyses are increasingly used for characterising the pharmacodynamic response of primary BC. This includes assessing ER+ BC's dependence on estrogen (E) by measuring gene expr changes after AI-treatment. However, di
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e0619d010237fcb4078f1a80fdf1b1db
https://doi.org/10.1158/1538-7445.sabcs16-p2-09-02
https://doi.org/10.1158/1538-7445.sabcs16-p2-09-02
Autor:
Anthony Skene, M Graf, Elizabeth Mallon, Judith M Bliss, Kieran Horgan, Simone Detre, J Banerji, James P Morden, Andrew Dodson, Margaret Hills, Andrew Evans, I. E. Smith, Mitchell Dowsett, Alexa Gillman, Christopher Holcombe, Lila Zabaglo, J.F.R. Robertson, V Raghavan
Publikováno v:
Cancer Research. 77:P2-05
Background Higher levels of the proliferation marker Ki67 at breast cancer (BC) diagnosis are increasingly recognised to indicate poorer prognosis. Change in ΔKi67 in response to endocrine treatment reflects response. The precise relationship betwee
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d062ecd92e147d95533b0bdef58429ae
https://doi.org/10.1158/1538-7445.sabcs16-p2-05-01
https://doi.org/10.1158/1538-7445.sabcs16-p2-05-01
Autor:
Nadia Harbeck, Joyce O'Shaughnessy, J. Cortés, M. Campone, Frances M. Boyle, Erika Hamilton, Joanne Cox, M. Martin, M. Toi, Z-M Shao, Patrick Neven, I. E. Smith, R. Wei, Roberto Hegg, Jung Ho Sohn, Valentina Guarneri, Martin Frenzel, Desiree Headley, Priya Rastogi, S.R.D. Johnston
Publikováno v:
Annals of Oncology. 31:S1143-S1144
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8e7beef7f93bce85a98e61969c61c7b8
https://doi.org/10.1016/j.annonc.2020.08.2238
https://doi.org/10.1016/j.annonc.2020.08.2238
Autor:
Mitchell Dowsett, Maggie Wilcox, Cliona C. Kirwan, Elizabeth Mallon, Andrew Dodson, Raghavan Vidya, James P Morden, J Banerji, Kieran Horgan, M Sibbering, J.F.R. Robertson, I. E. Smith, Andrew Evans, Judith M Bliss, Christopher Holcombe, Mcu Cheang, Anthony Skene, Lucy Kilburn
Publikováno v:
Cancer Research. 78:GS1-03
Background Experimental evidence (Fisher et al, 1989) & a small clinical trial (IMPACT) respectively suggested peri-operative endocrine therapy (ET) may improve long-term disease-related outcome in patients undergoing primary surgery for ER positive
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cd358aa04229b18107c25c691c071451
https://doi.org/10.1158/1538-7445.sabcs17-gs1-03
https://doi.org/10.1158/1538-7445.sabcs17-gs1-03
Autor:
K E M Blomberg, A. Hamasy, C. I. E. Smith, Anna Berglöf, Mauno Vihinen, Liang Yu, Dara K. Mohammad, Qing Wang
Publikováno v:
Leukemia
Irreversible Bruton tyrosine kinase (BTK) inhibitors, ibrutinib and acalabrutinib have demonstrated remarkable clinical responses in multiple B-cell malignancies. Acquired resistance has been identified in a sub-population of patients in which mutati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18262eda30c93529b5d145efe4cd1c8b
https://doi.org/10.1038/leu.2016.153
https://doi.org/10.1038/leu.2016.153
Autor:
Blazej A. Wojtczak, Edward Darzynkiewicz, Jacek Jemielity, Pedro Moreno, Roger Strömberg, Malgorzata Honcharenko, Joanna Romanowska, Burcu Bestas, Martina Jezowska, C. I. E. Smith, S. M. Bächle
Publikováno v:
RSC Advances. 6:51367-51373
Achieving higher nuclear concentrations by active transport may give potent therapeutic effects at lower doses for many drugs. A method of increasing nuclear uptake is the use of naturally existing Nuclear Localization Signals (NLS) by conjugating NL
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c2b04a438830210a988ba824574bcdcb
https://doi.org/10.1039/c6ra09568b
https://doi.org/10.1039/c6ra09568b
Autor:
Eva Kimby, Marzia Palma, A. Hamasy, Anders Österborg, C. I. E. Smith, Stephan Meinke, Robert Månsson, Anna Berglöf, Aleksandra Krstic
Publikováno v:
Scandinavian Journal of Immunology
Ibrutinib (Imbruvica™) is an irreversible, potent inhibitor of Bruton's tyrosine kinase (BTK). Over the last few years, ibrutinib has developed from a promising drug candidate to being approved by FDA for the treatment of three B cell malignancies,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c54282aacd92a42dd0fecb7311f59701
https://doi.org/10.1111/sji.12333
https://doi.org/10.1111/sji.12333